Peptide News Digest

Novo EASL ESSENCE Liver Safety, Parabilis IPO Zolucatetide, 20n Bio $7.5M Cyclic Peptide AI, 5W GLP-1 AI Citation Index, CAMPER MRSA Peptide

Novo Nordisk pre-EASL ESSENCE liver safety, Parabilis IPO for zolucatetide, 20n Bio cyclic peptide AI, 5W AI citation index, CAMPER anti-MRSA peptide.

10 stories · Covering clinical-trials, industry, research, regulatory

Editor's Note

A week ahead of EASL Barcelona, Novo's pre-conference ESSENCE liver safety drop reframes semaglutide from a weight-loss anchor to a multi-organ asset, and the 5W AI Visibility Index — where Novo and Lilly capture nearly all GLP-1 citations across ChatGPT, Claude, and Perplexity — clarifies how a two-company narrative monopoly is now being built into the AI substrate itself. The non-GLP-1 side keeps cashing checks and shipping science: 20n Bio's Seed+ pairs a high-throughput cyclic peptide platform with Lannacheng's radionuclide drug conjugate ambitions in China, Parabilis Medicines files for IPO to push helical-peptide zolucatetide into Phase 3 for desmoid tumors, and CAMPER's mechanistic AI drops a topical anti-MRSA candidate into the AMR pipeline. Meanwhile, the GLP-1 litigation count keeps climbing in Judge Marston's Eastern District of Pennsylvania court — 3,636 GI cases plus 86 NAION cases — and the ECO 89,718-patient breakdown shows just how widely outcomes scatter once trial cohorts are replaced by everyone actually using the drugs in the wild.

Clinical Trials

Novo Nordisk Pre-EASL 2026 Data Drop (May 19): ESSENCE Liver Safety Analysis Confirms Favorable Hepatic Profile for Semaglutide 2.4 mg in MASH

Eight days ahead of EASL Congress 2026 in Barcelona (May 27-30), Novo Nordisk released new analyses from the Phase 3 ESSENCE program showing semaglutide 2.4 mg holds a favorable hepatic safety profile across MASH subgroups, including the first dedicated Japanese MASH cohort and a women-in-menopause subset. Gastrointestinal events remained the leading adverse-event signal, with small discontinuation rates. MASH affects an estimated 250 million people globally with roughly 9 in 10 cases undiagnosed; the trial data reinforce the FDA's August 2025 MASH-with-fibrosis approval and broaden the prescribing case ahead of the EASL plenaries.

#novo-nordisk #semaglutide #essence-trial #mash #easl-2026 #hepatic-safety #japanese-cohort #menopause
Industry

5W Weight Loss & Metabolic Health AI Visibility Index (May 19): Novo Nordisk + Eli Lilly Capture Nearly 100% of GLP-1 Citations Across ChatGPT, Claude, and Perplexity

5W Public Relations published the fourth installment of its AI Visibility Index, finding two manufacturers — Novo Nordisk and Eli Lilly — account for nearly 100% of GLP-1-class citations inside ChatGPT, Claude, Perplexity, and Google AI Overviews. Five products — Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda — capture about 57% of all weight-loss-and-metabolic-health category citations. Founder Ronn Torossian attributes the citation moat to peer-reviewed clinical data cadence, named-author editorial coverage, and regulatory events treated as content events, with content velocity outpacing the broader news cycle.

#5w-pr #ai-visibility-index #novo-nordisk #eli-lilly #glp-1 #chatgpt #perplexity #media-analytics
Industry

20n Bio Closes US$7.5M Seed+ (May 20) for AI-Enabled Cyclic Peptide Discovery Platform, Pairs With Lannacheng on Radionuclide Drug Conjugate Pipeline

20n Bio announced a $7.5 million Seed+ round May 20 led by a strategic industry investor with participation from a London-based life-sciences VC. Proceeds advance the company's high-throughput cyclic peptide platform — which screens libraries of up to 10 trillion sequences — and integrate AI into the discovery workflow. 20n is a Bayer Co.Lab resident and has a January 2026 long-term partnership with Yantai Lannacheng Biotechnology to develop next-generation radionuclide drug conjugates, leveraging Lannacheng's clinical translation and manufacturing for precision oncology programs.

#20n-bio #cyclic-peptide #ai-drug-design #seed-financing #lannacheng #radionuclide-drug-conjugate #bayer-colab #precision-oncology
Industry

Parabilis Medicines Files S-1 for IPO (May 19): Helical-Peptide Zolucatetide Posts 74% Objective Response in 19-Patient Desmoid Cohort Ahead of Phase 3

Parabilis Medicines (formerly FogPharma) filed its S-1 on May 19 to list on Nasdaq under ticker PBLS, seeking ~$100M to fund Phase 3 of zolucatetide (FOG-001), a stabilized helical peptide and the first direct inhibitor of the β-catenin:TCF interaction. As of February 16, 38 desmoid-tumor patients were dosed; 25 had sufficient follow-up to be response-evaluable, all showed tumor reduction, and 74% of the 19 patients with ≥2 post-baseline scans hit RECIST 1.1 objective response. The IPO follows a $305M Series F in January and a Regeneron research deal worth up to $2B. FDA granted fast track designation for desmoid tumors.

#parabilis-medicines #fogpharma #zolucatetide #fog-001 #helical-peptide #beta-catenin #desmoid-tumors #ipo #regeneron
Research

Nature Communications: CAMPER Mechanistic AI Designs WP-CAMPER1 — 12-mer Peptide That Kills MRSA at 4 µg/mL and Reduces Skin-Infection Burden 2.5 log10 in Mice

Fadi Shehadeh, Biswajit Mishra and collaborators published CAMPER (Constraint-driven AMP Engineering with Ranking) in Nature Communications 2026, integrating machine learning with mechanistic biological features to design peptides that target MRSA persister cells. The lead candidate, WP-CAMPER1, kills S. aureus MW2 at a minimal inhibitory concentration of 4 µg/mL. A 2% topical formulation reduced bacterial burden 2.5 log10 in a murine prophylactic skin infection model; the D-enantiomer WP-CAMPER1-d achieved 1.37 log10 reduction in established biofilm infections.

#camper #wp-camper1 #antimicrobial-peptides #mrsa #persister-cells #nature-communications #ai-drug-design #biofilm
Industry

GLP-1 Litigation Tracker (May 2026): MDL 3094 Hits 3,636 GI Cases + MDL 3163 Reaches 86 NAION Vision-Loss Cases Before Judge Marston (E.D. Pa.)

Two federal multidistrict litigations against GLP-1 manufacturers continue to expand. MDL 3094 — In Re: Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation — now consolidates 3,636 cases alleging gastrointestinal injury, including gastroparesis and severe vomiting. MDL 3163, created December 15, 2025 after the JPML approved consolidation of vision-loss cases tied to non-arteritic anterior ischemic optic neuropathy (NAION), holds 86 cases as of May 6. Both sit before Judge Karen S. Marston in the Eastern District of Pennsylvania; no bellwether trial has been scheduled and no global settlement is in negotiation.

#mdl-3094 #mdl-3163 #glp-1-litigation #gastroparesis #naion #vision-loss #judge-marston #products-liability
Clinical Trials

Real-World ECO 2026 Analysis (May 18): 89,718-Patient Cohort Shows BMI Reduction Tiers Track With Obesity-Related Risk Outcomes; 20.8% Gained Weight

An ECO 2026 analysis covered May 18 by ScienceDaily examined 89,718 patients starting GLP-1 therapy — 75.6% semaglutide, 17.5% tirzepatide, 6.9% liraglutide — and stratified BMI change at year one. In the first year, 27% reduced BMI by less than 5%, 22.4% by 5-10%, 14.1% by 10-15%, and 15.8% by ≥15%, while 20.8% actually gained weight. Greater weight loss correlated with larger reductions in obesity-related risk endpoints; patients who gained weight after starting treatment faced worse health outcomes than untreated comparators in several measures.

#eco-2026 #real-world-evidence #semaglutide #tirzepatide #liraglutide #bmi-reduction #discontinuation #responder-analysis
Research

Nature Communications (May 15): Crystalline Mesoporous Frameworks Self-Assembled From Amphiphilic Collagen-Mimetic Peptides Open New Biomaterials Route

A Nature Communications paper details crystalline mesoporous frameworks built from amphiphilic collagen-mimetic peptides (aCMPs) — charge-segregated collagen-mimetic sequences modified with lipid tails at their N-termini. Hydrophobic and electrostatic interactions drive 3D porous architectures whose lattice packing tracks with lipid-tail length (C12, C10, C8); shortening to C6 flips assembly into nanosheets. The work expands peptide-based biomaterials beyond the triple helix and offers a programmable scaffold platform for drug delivery and tissue engineering.

#collagen-mimetic-peptide #mesoporous-framework #nature-communications #self-assembly #biomaterials #amphiphilic-peptide #drug-delivery
Regulatory

Pharmacy Times CME Virtual Event (May 19): 'Peptides Are Everywhere—So It's Time for a Serious Conversation'

Pharmacy Times hosted a CME-eligible virtual symposium May 19 (1:00-2:30 PM EDT) framing the post-RFK Jr. peptide moment for hospital and retail pharmacists. The agenda crossed the wellness-clinic side (BPC-157, TB-500, CJC-1295, GHK-Cu after the April 22 503A Category-2 removal) with the FDA-approved peptide side (semaglutide, tirzepatide, liraglutide, navepegritide, paltusotine) and walked attendees through the July 23-24 PCAC vote calculus and patient counseling around compounded GLP-1 risk.

#pharmacy-times #cme-webinar #peptide-compounding #503a-bulks-list #pcac #patient-counseling #pharmacist-education #rfk-jr
Research

Cell Biomaterials Review (April 16): AI-Driven Antibiotic Discovery Across Predictive + Generative Strategies for Small Molecules and Peptides

A Cell Biomaterials review published April 16 maps the AI-driven antibiotic-discovery landscape across two strategy families: mining (using discriminative models on genomic/proteomic sequence libraries) and generation (using diffusion and language models to design novel synthetic peptides exceeding nature's repertoire). Companion work flagged in the review includes the University of Pennsylvania AMP-Diffusion system, which produced tens of thousands of candidate peptides — 46 prioritized, three quarters bacterial-inhibitory, and two with in vivo efficacy matching approved antibiotics in mouse infection models.

#cell-biomaterials #ai-antibiotic-discovery #antimicrobial-peptides #amp-diffusion #university-of-pennsylvania #generative-ai #drug-resistant-bacteria #review-article